Cargando…
Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior
Obesity is a multifactorial disease, which in turn contributes to the onset of comorbidities, such as diabetes and atherosclerosis. Moreover, there are only few options available for treating obesity, and most current pharmacotherapy causes severe adverse effects, while offering minimal weight loss....
Autores principales: | Oliveira, Tadeu P. D., Gonçalves, Bruno D. C., Oliveira, Bruna S., de Oliveira, Antonio Carlos P., Reis, Helton J., Ferreira, Claudia N., Aguiar, Daniele C., de Miranda, Aline S., Ribeiro, Fabiola M., Vieira, Erica M. L., Palotás, András, Vieira, Luciene B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902877/ https://www.ncbi.nlm.nih.gov/pubmed/33642987 http://dx.doi.org/10.3389/fnins.2021.631311 |
Ejemplares similares
-
Metabotropic glutamate receptor 5 knockout rescues obesity phenotype in a mouse model of Huntington’s disease
por: Santos, Rebeca P. M., et al.
Publicado: (2022) -
The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer’s Disease
por: de Lima, Izabella B.Q., et al.
Publicado: (2023) -
Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas
por: Pereira, Mery Stefani Leivas, et al.
Publicado: (2017) -
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
por: Hovelsø, N, et al.
Publicado: (2012) -
Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease
por: Doria, JG, et al.
Publicado: (2013)